drugset / Trial / NCT04987294
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this Phase IIa study is to evaluate the safety, tolerability and pharmacodynamics of ALLN-346 in subjects with hyperuricemia and gout, and with mild to moderate chronic kidney disease.
Timeline
- Start
- 2022-09-02
- Primary completion
- 2022-09-02
- Completion
- 2022-09-02
Outcome
Outcome not reported
Stopped (Business): “Company Financing”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALLN-346 | Protein / enzyme biologic | — | Oral |